News Search Results
Oct 14, 2025, 09:00 ET Luminopia Recognized on Fast Company's Next Big Things in Tech List
results were published in Ophthalmology, leading to the initial FDA approval for patients aged 4 to 7 years. Based on the robust real-world evidence collected through the PUPiL Registry,
More news about: Luminopia
Oct 14, 2025, 07:00 ET Mallinckrodt Recognizes First Hepatorenal Syndrome (HRS) Awareness Day
diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients.
More news about: Mallinckrodt plc
Oct 13, 2025, 09:30 ET Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more. Co-Diagnostics will be meeting with institutional investors
More news about: Co-Diagnostics
Oct 13, 2025, 07:57 ET Orbis International's Flying Eye Hospital Returns to Ghana to Train Local Eye Care Teams
local health institutions to bolster the nation's eye care system and reduce avoidable vision loss. The program started with a focus on pediatric ophthalmology at KATH, providing training for eye care professionals, essential medical equipment, and financial assistance to families unable to afford treatment.
More news about: Orbis International
Oct 13, 2025, 07:00 ET Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting
with photoreceptor loss and vision impairment due to retinal degeneration, today announced multiple presentations at the American Academy of Ophthalmology (
More news about: Nanoscope Therapeutics
Oct 10, 2025, 09:00 ET Foundation Fighting Blindness Marks World Mental Health Day with Upcoming Webinar for Eye Care Professionals: Seeing Beyond Vision Loss - A Focus on Mental Health Resources for Patients with Retinal Disease
@BadassBlindBabe, raising awareness about disability and vision loss. Sandeep Grover, MD is Professor of Ophthalmology and Associate Chair at the University of Florida, Jacksonville. He directs the Inherited Retinal Diseases and Electrophysiology service, with research
More news about: Foundation Fighting Blindness
Oct 10, 2025, 07:45 ET Happiest Health launches Happiest Ayurveda clinic
Healthcare services (HCS) business specializes in multiple disciplines. We currently offer Dental and Orthopedic services. We will soon offer ENT, Ophthalmology, Pediatrics, Obesity & Weight management, Urology and other disciplines. The Wellness business too has a range of clinics
More news about: Happiest Health Systems Pvt LTD
Oct 09, 2025, 18:56 ET Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions
More news about: Celltrion
Oct 09, 2025, 09:05 ET Parker Waichman LLP Files Lawsuit on behalf of Florida Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from
More news about: Parker Waichman LLP
Oct 09, 2025, 07:05 ET REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-vec) for the treatment of diabetic retinopathy (DR) at the American Academy of Ophthalmology 2025 Annual Meeting. Sura-vec, developed in collaboration with AbbVie, is an investigational one-time gene therapy and potential first-in-class
More news about: REGENXBIO Inc.
Oct 09, 2025, 07:00 ET InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
More news about: InMode Ltd.
Oct 08, 2025, 19:30 ET Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) will be highlighted at the upcoming American Academy of Ophthalmology Annual Meeting (AAO 2025), October 18-20, in Orlando, Fla.
More news about: Astellas Pharma Inc.
Oct 08, 2025, 09:00 ET Luminopia Awarded on TIME's List of the World's Top HealthTech Companies 2025
results were published in Ophthalmology, leading to the initial FDA approval for patients aged 4 to 7 years. Based on the robust real-world evidence collected through the PUPiL Registry,
More news about: Luminopia
Oct 07, 2025, 15:25 ET ZEISS Report Reveals Link Between Quality and U.S. Manufacturing Success
quality assurance, microscopy solutions for life sciences and materials research, and medical technology solutions for diagnostics and therapy in ophthalmology and microsurgery for its customers. ZEISS also stands for the world's leading lithography optics, which is used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Oct 07, 2025, 10:25 ET Verana Health Enhances MIPS Advisory Services to Help Medical Practices to Maximize Program Benefits, Reduce Compliance Burden, and Improve Patient Care
Introduction of expanded coaching and advisory services coincides with 2025 American Academy of Ophthalmology Annual Meeting SAN FRANCISCO, Oct.
More news about: Verana Health
Oct 07, 2025, 10:19 ET Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Exchange. Kissei specializes in the development and commercialization of innovative therapies in key areas including urology, dialysis, women's health, ophthalmology, endocrinology, and metabolism. In addition to pharmaceuticals, the company provides therapeutic and care foods, as well as services such as healthcare
More news about: Apotex Inc.
Oct 07, 2025, 09:00 ET ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization
Business Unit Ophthalmology at ZEISS Medical Technology. "We're delivering important enhancements to our expanding portfolio across ZEISS and DORC solutions to meet the growing needs of ophthalmologists worldwide," said PT Cheong, Head of Global Sales for Ophthalmology, ZEISS Medical
More news about: Carl Zeiss Meditec AG
Oct 07, 2025, 09:00 ET ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization
Business Unit Ophthalmology at ZEISS Medical Technology. "We're delivering important enhancements to our expanding portfolio across ZEISS and DORC solutions to meet the growing needs of ophthalmologists worldwide," said PT Cheong, Head of Global Sales for Ophthalmology, ZEISS Medical
More news about: Carl Zeiss Meditec AG
Oct 06, 2025, 16:22 ET Mann Eye Institute Research Team Publishes Groundbreaking Study on Topography-Guided LASIK Outcomes
titled "Patient Reported Visual Outcomes, Dry Eye Symptoms, and Satisfaction Following Topography-Guided LASIK," has been published in Clinical Ophthalmology and represents a major advancement in understanding patient outcomes following modern LASIK procedures.
More news about: Mann Eye Institute
Oct 06, 2025, 09:30 ET Octane Medical Innovation Forum Oct. 28-29
Foundation board member. Mazzo has years of dedicated experience in the medical device industry including cardiology, dermatology, orthopedics, and ophthalmology. Additionally, forum judges will hear capital and growth presentation pitches from 14 entrepreneurs on stage.
More news about: Octane
Oct 06, 2025, 09:00 ET Westcove Advises Coastal Research Institute in its Partnership with Rovia Clinical Research
physician-embedded sites. With 14 sites and 80 investigators, Rovia focuses on endocrinology, obesity, cardiology, gastroenterology, neurology, ophthalmology, and infectious disease. Focused on operational excellence and patient access, Rovia supports its partners in conducting research efficiently while
More news about: Westcove Partners, LLC
Oct 02, 2025, 10:35 ET Verana Health Introduces Significant Data and Software Enhancements to Support Ophthalmologic Research and Treatment Optimization
expedite treatment options in ophthalmology. The announcements come ahead of the AAO 2025 Annual Meeting in Orlando, Florida, October 18-20. Verana Health is the exclusive data curation and analytics partner of the American Academy of Ophthalmology (Academy) IRIS® Registry
More news about: Verana Health
Oct 02, 2025, 08:30 ET Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Oct 01, 2025, 15:02 ET Renowned Glaucoma and Cataract Specialist Dr. Vinay Dewan Joins OCLI Vision in Nassau County
with a compassionate and innovative approach. Before joining OCLI Vision, Dr. Dewan completed a glaucoma fellowship and ophthalmology residency at the University of Texas Southwestern in Dallas, TX. He earned his medical degree from Washington University School of Medicine in St.
More news about: OCLI Vision
Oct 01, 2025, 07:30 ET Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental,
More news about: Biocon Biologics